Sponsor: ECOG-ACRIN Cancer Research Group
Sponsor Study ID: EA5221
Study Title: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
CTO #: 104067
NCT Number: NCT06096844
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: To evaluate whether there is an improvement in overall survival (OS) with chemotherapy combined with pembrolizumab compared to single agent pembrolizumab in this vulnerable older adult patient population.